Search results
Pharmaceutical intellectual property (IP) – incentives and rewards are the foundation on which innovation is built: they encourage and protect innovation, driving research and development investments into areas of unmet medical need.
- Rare Disease
30 million people in Europe live with a rare disease....
- Sustainable Innovation and The Need for a Carefully Balanced Intellectual Property Incentives System
The importance of intellectual property (IP) awards and...
- Guest Blog
By Bruno Henggi, Interpharma, Switzerland The protection of...
- Stimulating The Development of New Medicines for Children
Towards a ‘child-centric’ approach. The EU Paediatric...
- Lilly's Alzheimer's Quest
With over 7,000 medicines in development, new treatments...
- Isentress
Isentress - Intellectual Property - EFPIA
- PMR
PMR - Intellectual Property - EFPIA
- 100 Years of Protecting Innovation in Poland. Until Now
On November 26th, I had the honour of attending the jubilee...
- Rare Disease
28 paź 2020 · This article argues that strategic patenting by pharmaceutical companies requires a long-overdue intervention by competition authorities. It aims to attract their attention to the harmful effects of strategic patenting.
1 sty 2023 · This entry reviews many of the key issues and dilemmas that surround pharmaceutical patent protection and its impact on innovation.
13 kwi 2022 · Obtaining European patent protection for medical uses of known products is not a key factor limiting repurposing activity. Drug repurposing is a strategy for identifying new uses of approved or...
A robust, time-limited system of patent protection is proven to facilitate development of, and access to, innovative pharmaceutical products and processes. In particular, a well-functioning patent protection system is a prerequisite for attracting finance for costly pharmaceutical research, given its high failure
9 lis 2021 · European Patent Office data show an increasing number of patents for new medical uses of known products. Most countries active in pharmaceutical innovation provide some sort of patent...
Supplementary protection certificates (SPCs) are an intellectual property right that serve as an extension to a patent right. They apply to specific pharmaceutical and plant protection products that have been authorised by regulatory authorities.
